Results 1 to 10 of about 5,502 (184)

Impact of maintenance dose of eptifibatide in patients with ST-segment elevation myocardial infarction who underwent primary percutaneous coronary intervention [PDF]

The Egyptian Heart Journal, 2023
Background ST-segment elevation myocardial infarction (STEMI) is usually caused by a rupture in the atherosclerotic plaque, followed by platelet aggregation which ultimately leads to acute coronary artery occlusion.
Rozita Jalalian, Babak Bagheri, Jamshid Yazdani Charati, Shahrnaz Khalaghi, Mohammadreza Iranian, Mahsa Mohammadi   +5 more
doaj   +3 more sources

Protective effects of combined eptifibatide and ticagrelor in patients with unstable angina undergoing percutaneous coronary intervention: a single-center experience [PDF]

BMC Cardiovascular Disorders
Background We evaluated the safety and effectiveness of combined eptifibatide and ticagrelor in patients with unstable angina pectoris undergoing percutaneous coronary intervention (PCI).
Shangsong Shi, Zicheng Ling, Shaohua Gu, Tingbo Jiang, Lin Ling   +4 more
doaj   +3 more sources

Administration of eptifibatide as rescue therapy during mechanical thrombectomy in acute ischemic stroke [PDF]

Frontiers in Neurology
BackgroundThe success of the technical implementation of mechanical thrombectomy (MT) depends on many factors. Considering the experience of the interventional radiologist and the anatomical vascular differences of individual patients, it has technical ...
David Cernik, David Cernik, Jiri Neumann, Jarmila Neradova, Veronika Hlinena, Pavol Viglas, Pavol Viglas, David Cihlar, Filip Cihlar   +8 more
doaj   +3 more sources

A woman with eptifibatide (integrilin)‐induced thrombocytopenia following treatment of a clot in her coronary artery: A case report and literature review [PDF]

Clinical Case Reports
Eptifibatide, a GPIIb/IIIa receptor inhibitor, has shown its efficacy and safety in patients with high clot burden in their coronary vessels. It is widely used in patients with this condition.
Morteza Safi, Roozbeh Nazari, Nahid Senobari, Homa Taheri, Pouya Ebrahimi   +4 more
doaj   +3 more sources

Comparative Effects of Glenzocimab and Eptifibatide on Bleeding Severity in 2 Mouse Models of Intracranial Hemorrhage [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Antiplatelet drugs represent potential candidates for protecting the penumbral microcirculation during cerebral ischemia and improving the benefits of arterial recanalization in ischemic stroke.
Sébastien Dupont, Héloïse Lebas, Sabrina Mavouna, Eloïse Pascal, Astride Perrot, Adrien Cogo, Marie‐Charlotte Bourrienne, Carine Farkh, Mialitiana Solo Nomenjanahary, Véronique Ollivier, Fatima Zemali, Bernhard Nieswandt, Stéphane Loyau, Martine Jandrot‐Perrus, Eric Camerer, Jean‐Philippe Desilles, Mikael Mazighi, Yacine Boulaftali, Benoît Ho‐Tin‐Noé   +18 more
doaj   +3 more sources

A rare case of eptifibatide-induced thrombocytopenia [PDF]

Journal of Community Hospital Internal Medicine Perspectives, 2021
Eptifibatide is a glycoprotein (GP) IIb/IIIa receptor antagonist, used for the treatment of acute coronary syndrome with high-risk features or ongoing ischemia.
Khalil Kamar, Kira MacDougall, Mira Alsheikh, Sara Parylo, Yevgeniy Skaradinskiy   +4 more
doaj   +3 more sources

Safety and Efficacy of Low-Dose Eptifibatide for Tandem Occlusions in Acute Ischemic Stroke [PDF]

Neurology International
Objectives: The optimal treatment strategy for ischemic stroke in patients presenting with tandem occlusions of the internal carotid artery remains controversial.
Paweł Latacz, Tadeusz Popiela, Paweł Brzegowy, Bartłomiej Lasocha, Krzysztof Kwiecień, Marian Simka   +5 more
doaj   +3 more sources

Addition of eptifibatide and manual thrombus aspiration to ticagrelor does not improve long-term survival after STEMI treated with primary PCI [PDF]

Frontiers in Pharmacology
Background: Current guidelines recommend that glycoprotein IIb/IIIa inhibitor (GPI) and manual aspiration thrombectomy should not be routinely used in patients with ST-segment elevation myocardial infarction (STEMI) treated by primary percutaneous ...
Paul-Adrian Călburean, Paul-Adrian Călburean, Paul Grebenișan, Ioana-Andreea Nistor, Krisztina Pal, Krisztina Pal, Victor Vacariu, Reka-Katalin Drincal, Alissa Anamaria Ion, István Adorján, Tiberiu Oltean, László Hadadi   +11 more
doaj   +3 more sources

Acute Profound Thrombocytopenia Induced by Eptifibatide Causing Diffuse Alveolar Hemorrhage

Case Reports in Critical Care, 2021
Background. Eptifibatide is a glycoprotein IIb/IIIa (GP IIb/IIIa) receptor inhibitor which prevents platelet activation. The mechanism in which eptifibatide causes profound thrombocytopenia is poorly understood. One hypothesis suggests antibody-dependent
Gregory Byrd, Sabina Custovic, David Byrd, Deanna Ingrassia Miano, Jasdeep Bathla, Antonious Attallah   +5 more
doaj   +2 more sources

Early recovery of microvascular perfusion induced by t-PA in combination with abciximab or eptifibatide during postischemic reperfusion [PDF]

BMC Cardiovascular Disorders, 2002
Background GPIIb/IIIa inhibitors abciximab and eptifibatide have been shown to inhibit platelet aggregation in ischemic heart disease. Our aim was to test the efficacy of abiciximab (Reo Pro) or eptifibatide (Integrilin) alone or in combination with ...
Giusti Andrea, Bertuglia Silva
doaj   +2 more sources